SNAI1, ZEB1, E-cadherin (CDH1), and vitamin D receptor (VDR) genes regulate the epithelial-mesenchymal transition (EMT) that initiates the invasion process of many tumor cells. We hypothesized that this process could also affect the behavior of normal cells adjacent to the tumor. To verify this hypothesis, the expression level of these genes was determined by quantitative RT-PCR in tumor, normal adjacent, and normal distant tissues from 32 colorectal cancer (CC) patients. In addition, we extended the study to human HaCaT normal keratinocytes and SW480-ADH colon cancer cells co-cultured with SW480-ADH cells overexpressing the mouse Snai1 gene. Of 18 CC cases with SNAI1 expression in tumor tissue, five also had SNAI1 in normal adjacent tissue (NAT). Expression of SNAI1 in tumor tissue correlated with downregulation of CDH1 and VDR genes in both tumor (P ¼ 0.047 and P ¼ 0.014, respectively) and NAT lacking SNAI1 expression (P ¼ 0.054 and P ¼ 0.003). ZEB1 expression was directly related to VDR expression in tumor tissue (r ¼ 0.39; P ¼ 0.027) and inversely to CDH1 in NAT (r ¼ À0.46; P ¼ 0.010). CDH1 and VDR were also downregulated in SW480-ADH and MaCaT cells, respectively, when they were co-cultured with Snai1-expressing cells. Furthermore, cytokine analysis showed differences in the conditioned media obtained from the two cell types. These results indicate that histologically normal tissue adjacent to tumor tissue expressing the EMT-inducing gene SNAI1 shows alterations in the expression of epithelial differentiation genes such as CDH1 and VDR.
SNAI1, ZEB1, E-cadherin (CDH1), and vitamin D receptor (VDR) genes regulate the epithelial-mesenchymal transition (EMT) that initiates the invasion process of many tumor cells. We hypothesized that this process could also affect the behavior of normal cells adjacent to the tumor. To verify this hypothesis, the expression level of these genes was determined by quantitative RT-PCR in tumor, normal adjacent, and normal distant tissues from 32 colorectal cancer (CC) patients. In addition, we extended the study to human HaCaT normal keratinocytes and SW480-ADH colon cancer cells co-cultured with SW480-ADH cells overexpressing the mouse Snai1 gene. Of 18 CC cases with SNAI1 expression in tumor tissue, five also had SNAI1 in normal adjacent tissue (NAT). Expression of SNAI1 in tumor tissue correlated with downregulation of CDH1 and VDR genes in both tumor (P ¼ 0.047 and P ¼ 0.014, respectively) and NAT lacking SNAI1 expression (P ¼ 0.054 and P ¼ 0.003). ZEB1 expression was directly related to VDR expression in tumor tissue (r ¼ 0.39;
Introduction
Numerous studies have focused on the function of genetic abnormalities in various cancers, but very few of these analyzed their importance in normal tissue adjacent to tumors. Loss of heterozygosity (LOH) or allele imbalances (AI) at various chromosomal loci have been observed in normal tissue adjacent to tumor in breast and bladder cancer patients (Deng et al., 1996; Larson et al., 1998 Larson et al., , 2002 Lakhani et al., 1999; Forsti et al., 2001; Kurose et al., 2001; Li et al., 2002) . Moreover, other studies have reported gene and chromosome alterations in normal tissues, for example TP53 mutations in normal epidermis of patients with non-melanoma skin cancers (Ren et al., 1996) and in histologically normal tissue from the upper aerodigestive tract of cancer patients (Waridel et al., 1997) , or cytogenetic abnormalities and growth factor receptor overexpression in normal bronchial epithelium of lung cancer patients (Sozzi et al., 1991) . Recently, the importance of normal myoepithelial cells in breast cancer progression has been shown (Hu et al., 2008) . These studies proved the existence of alterations in normal tissues of cancer patients and suggested that these alterations might predispose individuals to local recurrence or may belong to the early stages of pathogenesis, in which case, they may suffer further complex and multiple genetic changes during tumor growth (Sozzi et al., 1991; Deng et al., 1996; Ren et al., 1996; Larson et al., 1998 Larson et al., , 2002 Lakhani et al., 1999; Forsti et al., 2001; Li et al., 2002) .
SNAI1 is a zinc-finger transcription factor that induces epithelial-mesenchymal transition (EMT) (Nieto, 2002) , a fundamental process in the early stages of carcinoma invasion and metastasis (Vleminckx et al., 1991; Perl et al., 1998; Peinado et al., 2007) . SNAI1 expression in epithelial cells promotes the acquisition of a fibroblastoid morphotype with invasive and migratory properties and characteristic changes in gene expression (Cano et al., 2000; Guaita et al., 2002) . Importantly, SNAI1 represses the CDH1 gene (Batlle et al., 2000) , which encodes E-cadherin, the main component of adherent junctions responsible for the maintenance of the adhesive and polarized phenotype of epithelial cells (Perez-Moreno et al., 2003) . CDH1 downregulation is one of the hallmarks of EMT. The transcription factor ZEB1 also downregulates CDH1 in cultured cells and cooperates with SNAI1 in inducing EMT (Grooteclaes and Frisch, 2000; Guaita et al., 2002; Peinado et al., 2007) . In contrast, vitamin D (1a,25-dihydroxyvitamin D 3 ) induces the expression of CDH1 and an epithelial phenotype in human colon cells expressing vitamin D receptor (VDR) (Palmer et al., 2001) . In addition, we showed that SNAI1 represses VDR expression in tumor cell lines and that its gene expression in human tumors is associated with CDH1 and VDR downregulation (Palmer et al., 2004; Pena et al., 2005) .
As some genetic alterations occur before the development of histologically abnormal tissue in cancer patients, and because of the interplay between SNAI1, ZEB1, CDH1 and VDR in the control of EMT, we hypothesized that expression of EMT genes (SNAI1, ZEB1) in tumors could affect expression of epithelial genes (CDH1, VDR) in normal adjacent tissue (NAT). Paracrine regulation by the tumor or other mechanisms could drive changes in the overall structure of normal tissue surrounding the tumor and facilitate tumor growth or invasion. It should not be forgotten that tissue remodeling occurs continuously during tumorogenesis (Herzig and Christofori, 2002) . To carry out this study, we analyzed the expression of these four genes in the tumor tissue and in histologically normal tissue adjacent to carcinoma in a series of 32 colorectal cancer (CC) patients. Some patients with SNAI1 expression in tumors also had SNAI1 expression in NAT. In addition, we found a correlation between expression of SNAI1 in the tumor and VDR and CDH1 downregulation in both tumor and NAT (not expressing SNAI1).
Results
Gene expression analysis of patient samples Expression of SNAI1, CDH1, VDR, and ZEB1 genes was studied in tumor (T) and histologically NAT in a series of 32 CC patients and related to expression found in normal tissue distant from the tumor (N).
SNAI1 was expressed in 18 out of 32 tumor samples (56.3%) and five of these patients also showed SNAI1 expression in the NAT (15.6%). These patients were excluded from the subsequent analysis to avoid misinterpretations of the results obtained. None of the normal distant tissues showed SNAI1 expression. The minimum, maximum, and median of VDR, ZEB1, and CDH1 expression in tumor and NAT are shown in Table 1 .
We detected SNAI1 protein, by immunohistochemistry, in the entire SNAI1 mRNA positive tumor tissues tested, but never in the NAT tissues, despite that was possible to detect SNAI1 mRNA in them (Figure 1) . Moreover, perceptible decrease in E-cadherin protein level in NAT tissue was observed in those cases with positive SNAI1 expression in their respective tumor tissues counterpart (Figure 1 ). Finally, SNAI1 protein was none detected in any of the normal tissues analyzed.
Study of the relation between gene expression levels A statistically significant association was observed between the presence of SNAI1 and the downregulation of CDH1 and VDR in tumor tissues: geometric averages of the VDR and CDH1 expression levels in those cases with SNAI1 presence in tumor tissue were, respectively, 0.52 and 0.83, compared with 2.04 and 3.57 when SNAI1 was not detected (P ¼ 0.014 and P ¼ 0.047, ANOVA) (Figure 2) .
Remarkably, presence of SNAI1 in tumor tissue but not in NAT was associated with downregulation of VDR and CDH1 in NAT (all of them SNAI1 negatives). Thus, of 13 cases with SNAI1 expression in tumor tissue but not in NAT, the geometric averages of VDR and CDH1 in NAT tissue were 0.85 and 0.84, respectively, against 4.75 and 3.38 in the 14 cases without SNAI1 expression in tumor tissue (P ¼ 0.003 and P ¼ 0.054, ANOVA) (Figure 2) .
No association between the presence of SNAI1 in tumor tissue and the expression of ZEB1 in tumor or in NAT was observed (P ¼ 0.351 and P ¼ 0.273, respectively, ANOVA) (Figure 2 ).
The study of the expression data of VDR, CDH1, and ZEB1 genes in tumor and NAT showed some correlations. As expected, a correlation between expression levels of CDH1 and VDR was observed in both tumor (r ¼ 0.58; Po0.001) and NAT (r ¼ 0.54; P ¼ 0.001). In addition, direct correlation between VDR and ZEB1 (r ¼ 0.39; P ¼ 0.027) was found in tumor tissue, but not in NAT. In contrast, when ZEB1 and CDH1 were related, inverse correlation in the NAT was observed (r ¼ À0.46; P ¼ 0.010), but not in the tumor tissue (Figure 3 ).
Analysis of K-RAS exon 1 mutation and LOH and microsatellite instability at 17q21 region To characterize at the molecular level, the histologically normal tissue adjacent to tumor, we studied K-RAS mutation and LOH and microsatellite instability in 17q21. Mutations in K-RAS exon 1 were found in 10 out of 32 tumor samples (31.3%). However, none of the samples of NAT or distant tissue showed mutations (Figure 4) .
Two of the five cases with SNAI1 expression in NAT (40%) had mutations in the exon 1 of K-RAS in the EMT genes in normal tissue adjacent to tumor C Peña et al tumor tissue, but none of them had in the NAT or distant tissue. We observed 4 out of 20 (20%) informative cases with LOH in 17q21 in 32 tumor samples. In addition, microsatellite instability was found in another patient. Similar to K-RAS mutations, neither NAT nor N tissues had LOH or microsatellite instability in 17q21 (Figure 4) .
To quantify the proportion of contaminating cells with low CDH1 expression levels present in a population of normal cells with high CDH1 expression levels, needed to justify the loss of CDH1 observed in our study, we extracted the mRNA from SW480-ADHMock cells mixed with different proportions of SW480-ADH-Snai1 (0, 10, 25 and 75%). There were 3.9-fold decreases in CDH1 levels in SW480-ADH-Snai1 versus SW480-ADH-Mock cells, and much >75% of SW480-ADH-Snai1 cells contaminating the SW480-ADHMock cells were required to obtain a notable decrease in CDH1 levels ( Figure 4 ).
Paracrine assays with human colon cancer cells
The results suggested that SNAI1-expressing tumor cells modify the expression of CDH1 and VDR in adjacent T NAT N Figure 1 Immunohistochemical analysis of SNAI1 (a) and E-cadherin (b) protein in the normal distant tissue (N), normal adjacent tissue (NAT) and tumor tissue (T) from one patient in which SNAI1 mRNA was detected both in NAT and T counterpart tissues. Despite SNAI1, mRNA was detected in T and NAT samples, SNAI1 protein was only detected in tumor tissue. A clear decrease in E-cadherin expression regarding normal tissue is observed both in T and NAT samples. Unlike results with CDH1, incubation of SW480-ADH-Mock cells with conditioned medium from SW480-ADH-Snai1 did not change VDR, ZEB1, or SNAI1 expression levels (Supplementary Table 2B ; Supplementary Materials).
Regulation of cytokines by Snai1
We further investigated whether Snai1 mediates the production and release of cytokines, growth factors, and other immuno-modulators by using a human cytokine array with conditioned medium from SW480-ADH- (Figure 6a ). After incubation, membranes were scanned and each cytokine was quantified by densitometry. Relative cytokine intensities were normalized in relation to control spots on the same membrane. A significant increase was observed in SW480-ADH-Snai1-conditioned medium for several cytokines. We observed a 9.5-fold upregulation change in MIP-3 a, together with significant increases in IL-6, GRO-a, MCP-3, and GCP-2, which were also upregulated in SW480-ADH-Snai1 cells, with an approximately 2.5-fold change from SW480-ADHMock (Figure 6b ). In contrast, other EMT-related factors such as TGFB1 did not show any alteration.
Proteomic assay
The aforementioned observations suggest that SW480-ADH-Snai1 cells supply paracrine signals that induce CDH1 downregulation in adjacent cells. To understand this process better, we compared the proteoma of the conditioned medium from SW480-ADH-Mock and SW480-ADH-Snai1 cells by 2D-DIGE and Peptide Mass Fingerprinting searching for differences in secreted proteins. We identified 22 differently expressed proteins (Table 2 ). Though none of these proteins have an acknowledged paracrine function, further studies are needed to substantiate whether any of them contributes to the downregulation of CDH1.
Discussion
Tumor invasion can be viewed as a deregulation in the proper sorting of cell populations, causing an alteration of normal tissue boundaries (Brown et al., 1999; Hanahan and Weinberg, 2000; Park et al., 2000) . It is generally accepted that physiological and malignant invasion use similar molecular mechanisms (Liotta et al., 1991) . Cross-talk between mesenchyme and epithelium has been considered as a driver of differentiation and development (Aboseif et al., 1999; Nilsson and Skinner, 2001 ) and has been viewed as involved in the promotion of epithelial transformation (Aboseif et al., 1999; Olumi et al., 1999; Li et al., 2000) . Altered cell-cell and cell-substratum signals may release normal tissue constraints, thereby enabling malignant cells to migrate across tissue boundaries (Liotta et al., 1991; Hanahan and Weinberg, 2000) .
The objective of our study was to search for alterations that may favor tumor progression and invasion in the expression levels of EMT-related genes in the normal tissue adjacent to tumor. The few such studies performed were mainly directed to the analysis of genetic or chromosome alterations, such as LOH and allelic instability at various chromosomal loci or TP53 mutations. Our study shows deregulation of genes involved in EMT in NAT that is associated with tumor characteristics. It could be argued that these results are masked by the presence of contaminating tumor cells in NAT. Nevertheless, we believe that this is highly improbable, as minor contamination not detectable by histological analysis should not justify the observed changes in a quantitative study, especially as we are looking at downregulation of particular genes such as CDH1. On the other hand, there were 3.7-fold decreases in CDH1 levels in NAT SNAI1 positive tissues versus NAT SNAI1-negative tissues; >75% of contaminating low CDH1 expressing cells were required to achieve these results. It is very difficult to believe that this high proportion of tumor cells invading the NAT tissue is not detected by the pathologist. Moreover, if contaminating tumor cells affect a quantitative analysis, their presence should also be detected by a qualitative analysis such as K-RAS mutation or allelic instability analysis. EMT genes in normal tissue adjacent to tumor C Peña et al
b). (II) SW480-ADH-Mock cells incubated for the times indicated with 24 h-conditioned medium from SW480-ADH-Mock cells (black columns) or SW480-ADH-Snai1 cells (gray columns) (a) or incubated for 24 h with medium conditioned for different times by SW480-ADH-Mock cells (black columns) or SW480-ADH-Snai1 cells (gray columns) (b).
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We suggest that the observed deregulation of SNAI1, CDH1, VDR, and ZEB1 genes in the normal tissue boundaries may result from the paracrine interaction between malignant and histological normal epithelium. Moreover, it has been described that changes in stromal cell population and remodeling of the extracellular matrix/basement membrane results in a breakdown of normal tissue boundaries and seems to be a necessary stage in the local invasion of tumor cells (Liotta et al., 1991; Vleminckx et al., 1991; Werb, 1997; Condeelis and Segall, 2003; Sahai and Marshall, 2003; Wolf et al., 2003) .
As expected, the expression of the two epithelial genes, VDR and CDH1, are strongly associated. Interestingly, when SNAI1 was expressed in tumor tissue, both CDH1 and VDR were downregulated not only in tumors but also in NAT. This relation may be a direct effect from tumor to normal adjacent cells, a secondary effect because of specific characteristics conferred on the tumor by SNAI1 expression or related to other unknown alterations. For example, changes in secreted matrix proteins by tumor cells could modulate the expression of CDH1 in adjacent cells through the activation of the integrin-linked kinase (Lochter et al., 1997; Wu et al., 1998; Menke et al., 2001 ). This effect might be mediated by SNAI1 activation in adjacent cells, as SNAI1 transcription is stimulated by integrinlinked kinase activation in colon cells (Tan et al., 2001) . This hypothesis is supported by the fact that SNAI1 was detected in five normal tissues adjacent to tumor in our series. Alternatively, as SNAI1-expressing tumors are more invasive (Cano et al., 2000; Guaita et al., 2002) , they are more prone to disrupt the boundaries established with neighboring tissues. Otherwise, although the mechanism remains unknown, the experiments with tumor cell lines showed that Snai1-expressing cells could paracrinally downregulate the expression of CDH1 and VDR in neighboring cells without changing the endogenous level of SNAI1. Human cytokine array showed several cytokines differentially released by tumor cells expressing SNAI1; most of these released cytokines have a major function in monocyte-macrophage recruitment and pro-inflammatory activities, opening an interesting link between SNAI1 and inflammation, which deserves further investigation. Likewise, it was recently described that SNAI1 proteins influence the behavior of Snai1-negative neighboring cells in zebrafish embryo (Blanco et al., 2007) . Although we performed a proteomic analysis looking for differences between conditioned media from SW480-ADH-Mock and SW480-ADH-Snai1, we did not identify proteins with an acknowledged paracrine function. However, several deregulated proteins of unknown function were characterized.
We found an inverse relation between the expression of ZEB1 and CDH1 genes in NAT, which was not observed in tumor tissue. It is possible that, in SNAI1-expressing tumors, the effects of ZEB1 on CDH1 were masked by SNAI1 effects, as this factor is a more potent repressor of CDH1 transcription (Guaita et al., 2002) . In addition, these two factors may cooperate in CDH1 repression or act on parallel pathways. This hypothesis is supported by our earlier studies with a large series of colorectal carcinoma, in which we found a loss of relation between SNAI1 expression and CDH1 downregulation when ZEB1 expression was high (Pena et al., 2005) . In addition, it should be remembered that the ability of ZEB proteins to work as transcriptional repressors or activators can be modulated by acetylation, a process that selectively allows ZEB proteins to EMT genes in normal tissue adjacent to tumor C Peña et al interact with co-repressors or co-activations such as p300 or CtBP (Postigo et al., 2003) . Different expression levels of ZEB1 cofactors, p300 and CtBP, in tumor or normal tissue may explain the different repressive activity on CDH1, and even the positive relationship detected in these tissues with VDR expression. It should also be remarked that transfection of ZEB1 into SW620 colon carcinoma cells results in the upregulation of endogenous VDR (Lazarova et al., 2001) . In fact, we earlier observed an inverse correlation between ZEB1 and CDH1 expression in tumor tissue when the cofactor CtBP was overexpressed and a stronger direct correlation between ZEB1 and VDR when the cofactor p300 was overexpressed (Pena et al., 2006) . In summary, the regulation of CDH1 and VDR seems to be different in tumor and NAT. SNAI1 and ZEB1 genes are expressed by mesenchymal cells (Batlle et al., 2000; Cano et al., 2000) and, presumably, by stromal cells. In this context, the results of SNAI1 or ZEB1 deregulation observed in tumor tissue might be influenced by the expression of these genes in non-epithelial cells, masking the expression in epithelial tumor cells. However, similar changes to those observed in the tumors were detected when using epithelial enriched cell populations in an earlier study (Pena et al., 2005) . Therefore, we conclude that alterations found in the expression of these genes in the whole tumor samples of this series correspond to carcinoma cells.
As for CDH1 expression, we observed in an earlier study that the quantification of CDH1 RNA in the whole biopsy is a good marker of E-cadherin expression and that non-significant intra-tumor differences were found in E-cadherin staining (Pena et al., 2005) , in contrast with other authors' findings (Brabletz et al., 2001) .
Our data add novel information about the behavior of tumor-normal tissue boundaries. We suggest that tumor-adjacent tissue considered as histologically and molecularly normal undergoes alterations in gene expression that may influence tumor progression and phenotypic features. These results support the need for further study of the signals involved in tumorstromal cross-talk, an approach that may bring therapeutic benefit.
Materials and methods
Patients, tumor samples, and RNA extraction This study, approved by the Research Ethics Board of our hospital, was based on a consecutive series of 32 patients who underwent surgery for CC between January 2004 and January 2005. Samples of tumor and of normal adjacent (taken 0.5 cm from the outer tumor margin) and normal distant (taken at least 3 cm from the outer tumor margin) tissues were obtained sequentially, immediately after surgery, snap-frozen in liquid nitrogen and stored at À80 1C until processing.
All formalin-fixed paraffin-embedded normal and tumor tissues were examined histologically by two independent pathologists to ensure that each type of tissue was correctly assigned to its corresponding group.
RNA was extracted from tumor and normal (both adjacent to and distant from tumor) samples with the RNeasy Mini Kit (Qiagen Inc., Hilden, Germany), according to manufacturer's protocol. The RNA extracted was quantified with a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA).
Real-time PCR
As SNAI1 RNA was not detected in normal distant tissues, SNAI1 expression in tumor and NAT was only valued as presence or absence. A SNAI1 retrogene, SNA1P, located at chromosome 2q34-X is very similar to SNAI1 (Locascio et al., 2002) . Expression of SNA1P in epithelial cell lines induces EMT and represses CDH1 expression, albeit less strongly than SNAI1 does (Locascio et al., 2002) . To amplify SNAI1, primers were designed from a region with 16 bp differences between SNAI1 and SNA1P. Amplification of SNA1P was thus avoided, which was checked by sequencing of the PCR fragments obtained. Primers used are shown in Supplementary Table 1. VDR, CDH1, and ZEB1 mRNA levels were calculated in the tumor and in normal adjacent and distant tissues by a relative quantification approach, in which the amounts in the targets were expressed in relation to the geometric average of three reference housekeeping genes: TATA binding protein, succinate dehydrogenase complex subunit A, and ubiquitin C (Palmer et al., 2004) . The relative concentrations of target and reference genes were calculated by interpolation, using a standard curve of each gene generated with a serial dilution of a cDNA prepared from RNA extracted from SW480-ADH cells. The expression level of a target gene in a patient was calculated as the ratio of its expression in T or NAT versus its expression in N (T/N or NAT/N). Primers used are shown in Supplementary Table 1. For the synthesis of the first strand of cDNA, 400 ng of total RNA were retro-transcribed using the Gold RNA PCR Core Kit (PE Biosystems, Foster City, CA, USA), following the manufacturer's instructions. Random hexamers were used for cDNA synthesis. Real-time PCR was performed in a LightCycler apparatus (Roche Diagnostics, Mannheim, Germany) using the LightCycler-FastStart PLUS DNA Master SYBR Green I Kit (Roche Diagnostics).
Analysis of K-RAS exon 1 mutation and LOH and microsatellite instability at 17q21 region PCR amplification of K-RAS gene and D17S855 microsatellite marker located at intron 20 of BRCA1 (17q21 region) was carried out from 100 ng of genomic DNA as template, using Ampli Taq DNA polymerase (Perkin-Elmer, Roche Molecular Systems Inc., Branchbur, NJ, USA). The allelic band intensity on the gels was detected by non-radioisotopic means with a commercially available silver staining method (Oto et al., 1993) . Primers used for amplification of K-RAS exon 1, containing codons 12 and 13, and for the 17q21 region were shown in Table 1 (Supplementary Materials). The bands with different mobility shift pattern were sequenced in an ABI Prism 377 DNA sequencer apparatus (PE Applied Biosystems, Foster City, CA, USA).
Co-culture and conditioned medium assays SW480-ADH (Tomita et al., 1992; Baulida et al., 1999) human colon cancer cells stably expressing mouse Snai1 cDNA (SW480-ADH-Snai1) or an empty vector (SW480-ADHMock) were generated by retrovirus-mediated gene transfer, as described earlier (Palmer et al., 2004) . Cells were cultured in Dulbecco's modified Eagle medium (Gibco Life Technologies, Gergy-Pontoise, France) containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, penicillin (100 units/ml), streptomycin (100 ng/ml), and fungizone (0.25 mg/ml) at 37 1C in a 5% CO 2 -humidified atmosphere.
Co-cultures of SW480-ADH-Mock, HaCaT, and SW480-ADH-Snai1 cells, physically separated, were grown in six-well plates using Transwells Permeable Supports (0.4 mm pore size, high pore density, Becton Dickinson, Le Pont-de-Claix, France). RNA was extracted from SW480-ADH-Mock and HaCaT cells after the indicated times of co-culture. RNA obtained from SW480-ADH-Mock cells co-cultured seeded in the two transwell chambers were always used as a control. All the experiments included controls in which SW480-ADHMock cells were seeded in both compartments.
To obtain conditioned mediums, the normal medium of SW480-ADH-Mock or SW480-ADH-Snai1 cells were replaced by half the volume of fetal calf serum-free medium as incubation was continued for the indicated times. The medium was then filtered and 10 Â concentrated using Amicon Ultra technology (Centrifugal filter devices, regenerated cellulose 10 000 MWCO, Millipore Corporation, Billerica, MA, USA). SW480-ADH-Mock cells were incubated with 10 Â concentrated conditioned medium, diluted 1:4 in normal medium for the times indicated.
Four repetitions were carried out for each experiment.
Human protein cytokine array SW480-ADH-Mock and SW480-ADH-Snai1 stably transfected cells were cultured at 37 1C in an atmosphere of 5% CO 2 for 48 h in Dulbecco's modified Eagle medium with 10% fetal calf serum. Then, they were washed with PBS and cultured for 24 h under the same conditions in Dulbecco's modified Eagle medium fetal calf serum-free medium. The conditioned medium was harvested, centrifuged at 1500 g to remove cell debris and filtered. Conditioned medium from each stable cell type was prepared and incubated with membranes containing an array of 80 human cytokine antibodies. The human protein cytokine array V membranes (RayBiotech, Norcross, GA, USA) were blocked in blocking buffer for 1 h, and then 2 ml of conditioned medium from each culture cell was individually (physically separated) added and incubated at 4 1C overnight. The membranes were then treated and analyzed according to the manufacturer's instructions. The experiment was repeated twice, with excellent reproducibility.
Proteomic assays
Protein content of conditioned media (24 h incubation) from SW480-ADH-Mock or SW480-ADH-Snai1 cells was analyzed by 2D-DIGE and the spots of interest were excised and identified by Peptide Mass Fingerprinting using MALDI-TOF-TOF MS (Text 1, Supplementary Materials).
Immunohistochemistry E-cadherin and SNAI1 protein were analyzed by immunohistochemistry in several samples taken from normal, tumor, and NAT tissues of the five patients, in which SNAI1 mRNA was detected. At the same time, one patient, in which SNAI1 mRNA was only detected in tumor tissue, was used as a control. The normal tissues of all of them were used as a negative control.
Immunophenotypic analysis was performed according to standard procedures, with overnight incubation in the presence of anti-E-cadherin DAKO antibody. Immunodetection was performed with peroxidase-labeled streptavidin biotin (LSA; Dako, Glostrup, Denmark) using diaminobenzidine chromagen as substrate. All immunostaining was performed using the TechMate 500 (Dako) automatic immunostaining device.
SNAI1 immunohistochemical staining was performed as follows: 2.5-mm-thick paraffin-embedded complete tissue sections were cut onto Dako slides (Dako), and subsequently dewaxed, rehydrated, and subjected to antigen retrieval using the Dako's PT Link with 10 mM of sodium citrate, at pH 9, and heated at 95 1C. The slides were cooled and treated with peroxidase-blocking solution (Dako) for 5 min. Sections were then immunostained with SNAIL (EC3 clone) (Franci et al., 2006) hybridoma supernatant by the two-stage peroxidasebased EnVision technique (Dako), counterstained with hematoxylin, and mounted. Incubations, either omitting the specific antibody or containing unrelated antibodies, were used as a control of the technique.
Data analysis
As the distribution of the gene expression values was not normal distributed (Kolmogozov-Smvinov test), to carry out the statistical analysis, we normalized data distribution by using log 10 . We used the geometric average of the T/N and NAT/N, instead of the arithmetical one, to describe the expression gene data because of the non-normal distribution of the data. Expression levels of CDH1 and VDR were contrasted with the presence or absence of SNAI1 expression in different tissue samples by ANOVA. CDH1, VDR, and ZEB1 expression levels were studied by the Pearson's test. Two-tailed P-values p0.05 were considered statistically significant. Statistical analysis used the SPSS statistical package, version 13.0.
Abbreviations AI, allele imbalance; CC, colorectal cancer; EMT, epithelialmesenchymal transition; LOH, loss of heterozygosity; N, normal; NAT, normal adjacent tissue; T, tumor; VDR, vitamin D receptor.
